Weight loss tablet might end up being a best-in-class drug

0
43
Novo Nordisk CEO on latest trials, U.S. obesity and demand outlook

Revealed: The Secrets our Clients Used to Earn $3 Billion

Novo Nordisk CEO Lars Fruergaard Jørgensen on Friday stated the business’s speculative weight-loss tablet, amycretin, might ultimately end up being a best-in-class treatment for weight problems.

The Danish drugmaker is racing to take advantage of the runaway success of its smash hit weight-loss drug Wegovy by establishing a brand-new generation of treatments for weight problems, consisting of easier and possibly more affordable tablets.

His remarks came one day after Novo Nordisk amazed financiers with early-stage trial information on amycretin. Patients on the tablet lost about 13.1% of their weight after 12 weeks, Jørgensen stated on CNBC’s “Money Movers.”

That goes beyond the 6% weight-loss seen in those who took Wegovy after the very same period. It likewise contributes to the growing interest around the capacity of weight-loss tablets.

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks throughout an interview in New York onAug 10, 2022.

Christopher Goodney|Bloomberg|Getty Images

Along with benefit for clients, tablets might assist reduce a few of the supply restrictions pestering weight-loss injections. Wegovy, in addition to comparable drugs, has actually skyrocketed in need and slipped into periodic scarcities over the previous year due to its capability to assist clients shed substantial weight with time.

“We believe in the future there’ll be different segments of anti-obesity treatments, with different patients having different preferences,” Jørgensen informed CNBC. “Some will prefer an injectable and we really believe that once we can take a pill, it’s a very convenient offering.”

But those tablets will not sign up with the marketplace at any time quickly. A midstage trial on amycretin will start in the 2nd half of this year, with outcomes anticipated in early 2026, the business statedThursday

In a different interview with Reuters on Friday, Novo Nordisk’s head of advancement Martin Holst Lange stated the business is comfy in having the ability to introduce amycretin this years.

Amycretin reduces cravings by targeting the very same gut hormonal agent that Wegovy mimics, which is called GLP-1. But amycretin likewise targets a pancreas hormonal agent called amylin, which impacts appetite.

U.S.-traded shares of Novo Nordisk increased as much as 8.3% on Thursday after the business launched the information, extending the previous year’s 68% gain. But the business’s stock fell 2% onFriday

Don’ t miss out on these stories from CNBC PRO: